Monte Rosa Therapeutics

Yahoo Finance • 25 days ago

Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Monte Rosa Therapeutics (NasdaqGS:GLUE) announced a new supply agreement with Johnson & Johnson to evaluate MRT-2359 with E... Full story

Yahoo Finance • 30 days ago

Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Monte Rosa Therapeutics, Inc. MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily pretrea... Full story

Yahoo Finance • 5 months ago

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and atherosclerosis Initial data from a Phas... Full story

Yahoo Finance • 5 months ago

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

Monte Rosa Therapeutics, Inc. Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option exercise p... Full story

Yahoo Finance • 5 months ago

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chi... Full story

Yahoo Finance • 6 months ago

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases

MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model Data support the potential of MRT-6160 to addr... Full story

Yahoo Finance • 7 months ago

Here are the top movers in Monday's session.

Here are the top movers in Monday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT ATCH [https://www.chartmill.com/stock/quote/ATCH/profile] 148.0% ATLASCLEAR HOLD... Full story

Yahoo Finance • 7 months ago

Which stocks are moving on Monday?

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT ATCH [https:... Full story

Yahoo Finance • 7 months ago

Monte Rosa Rockets 50% on $5.7B Novartis Licensing Deal

This article first appeared on GuruFocus. Novartis (NOVN, Financials) and Monte Rosa Therapeutics (GLUE, Financials) have signed a deal worth up to $5.7 billion to work together on medicines for disorders that affect the immune system. Un... Full story

Yahoo Finance • 7 months ago

Monte Rosa stock rises after pact with Novartis

[Communication concept] Shares of Monte Rosa Therapeutics (NASDAQ: NASDAQ:GLUE [https://seekingalpha.com/symbol/GLUE]) rose after it announced a new collaboration with Novartis (NYSE:NVS [https://seekingalpha.com/symbol/NVS]) to advance t... Full story

Yahoo Finance • 7 months ago

Monday's session: gap up and gap down stocks

Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. [gap] TOP GAP UP STOCKS TICKER CHANGE COMMENT NAOV [ht... Full story

Yahoo Finance • 7 months ago

Monday's pre-market session: top gainers and losers

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT GPUS [https://www.chartmi... Full story

Yahoo Finance • 7 months ago

Monte Rosa surges premarket on Novartis collaboration deal

Investing.com -- Monte Rosa Therapeutics shares have rallied in premarket trading on Monday, up 65.3% to $7.94 after the biotechnology company announced a new collaboration agreement with Novartis focused on developing molecular glue degra... Full story

Yahoo Finance • 7 months ago

Novartis, Monte Rosa strike $5.7 billion drug development deal

(Reuters) -Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases. (Reporting by Kamal Choudhury in Bengaluru; Editing b... Full story

Yahoo Finance • 7 months ago

Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics

(Reuters) - Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases. Under the agreement, Monte Rosa Therapeutics will re... Full story

Yahoo Finance • 7 months ago

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Monte Rosa Therapeutics, Inc. Novartisreceivesanexclusivelicensetoanundiscloseddiscoverytarget Novartis also receives options to license two programs from Monte Rosa’s growing preclinical immunology portfolio MonteRosatoreceiveanupfront... Full story

Yahoo Finance • 8 months ago

Validea Kenneth Fisher Strategy Daily Upgrade Report - 8/12/2025

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consi... Full story

Yahoo Finance • 8 months ago

Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Q2 2025 Earnings: Revenue Surges, Loss Narrower Than Expected

MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE [https://www.chartmill.com/stock/quote/GLUE]) REPORTS Q2 2025 EARNINGS: REVENUE BEATS, EPS NARROWER THAN EXPECTED Monte Rosa Therapeutics Inc posted second-quarter 2025 financial results that excee... Full story

Yahoo Finance • 9 months ago

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key downstream pharmacodynamic markers; initial resu... Full story

Yahoo Finance • 9 months ago

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

BOSTON, July 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the publication of groundbreak... Full story